Latest News

One year ago, an Idaho Falls couple was shocked to hear doctors say their twin boys were dying from a rare disease that eats at the muscle. Friends and family want to make sure that for however long the Devereaux boys live, their lives are full of joy and comfort....
Toronto, Ontario – The Global Alliance for Genomics and Health (GA4GH) and the International Neuroinformatics Coordinating Facility (INCF) launched a new group to lay the groundwork for connecting global neuroscience and genomic data. Answering data-driven questions in neuroscience means dealing with complexity: in types of data, data management systems, the...
COLUMBUS, Ohio – Two five-year grants totaling more than $6 million from the National Cancer Institute (NCI) will help The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) researchers and colleagues at other institutions better understand acute...
PARIS — Two landmark clinical trials reported today at the Union meeting showed that an oral antibiotic taken for six months once-daily substantially reduced the risk of developing drug-resistant TB. The antibiotic levofloxacin safely reduced the risk of multidrug-resistant (MDR) tuberculosis (TB) disease in children by 56%, researchers from the...
Stockholm, Sweden – There does not appear to be any profound differences between so-called exposure-based CBT and traditional CBT in the treatment of fibromyalgia, according to a study led by researchers at Karolinska Institutet. Both forms of treatment produced a significant reduction in symptoms in people affected by the disease....
Recall the saying “there are a thousand ways to skin a cat”? Researchers are rephrasing it in regard to the mosquito. Fifty years ago, we thought that the war against malaria was pretty much won. We had quinine and chloroquine, which were effective against the parasite that causes the disease....
ORLANDO — Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell cancer, which are...